Tabares-Trujillo MK, Aguilera-Pérez JR, Velázquez-Valassi B, Garza-Ríos P, Angulo-Torres LC, García-Ruiz R

Language: Spanish
References: 10
Page: 25-29
PDF size: 104.15 Kb.

ABSTRACT

Introduction: The incidence of cardiovascular disease and metabolic syndrome during the menopause is around 35%. The objective of this study was to establish the relation between anthropometric and biochemical values in those patients with metabolic syndrome with and without hormone replacement therapy during menopause. Methods: A retros­pective cohort study with case analysis of the Coordination of Peri and Postmenopause at the Instituto Nacional de Perinatología Isidro Espinosa de los Reyes during the period between 1998 and 2009; the study included those patients with diagnosis of metabolic syndrome. The variables analyzed were: a) anthropometric, b) biochemical indicators and c) blood pressure levels, divided in two groups: patients with hormone replacement therapy (Group I) and patients without hormonal therapy (Group II). The statistical analysis were performed depending on the variable, with chi-square, Student t test and OR, CI (95%). Results: 310 cases were included: Group I, 121 cases and Group II 189 cases. There were no statistically significant differences on anthropometric and biochemical indicators, but significant differences in cholesterol (p=0.024) and diastolic blood pressure levels, were found (p ‹0.001) in patients receiving hormone replacement therapy. Group II had an OR 5.27, CI 95% (2-13.87) for diastolic blood pressure› 90 mmHg. Conclusions: Patients with metabolic syndrome without hormone replacement therapy have an increased risk for diastolic blood pressure › 90 mmHg and a tendency to maintain higher cholesterol levels and increasing the risk of developing cardiovascular disease, although research on the different risk factors, and the implications of hormone therapy, are still insufficient to recognize the scale of the problem in the climacteric woman.

REFERENCES

1. Chu MC, Cushman M, Solomon R, Rogerio A, Lobo RA. Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers. Am J Obstet Gynecol 2008; 199: e1-7.

2. Hu P, Greendale GA, Palla SL, Reboussin PA, Herrington DM, Barret-Connor E et al. The effects of hormone therapy on the marks of inflammation and endothelial function and plasma matrix metalloproteinase–9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis 2006; 185: 347-52.

3. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V et al. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study: a randomized, double blind, placebo–controlled trial. Ann Intern Med 2003; 138: 1-9.

4. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993; 60: 664-7.

5. Chu MC, Cosper P, Nakhuda GS, Lobo RA. Comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Fertil Steril 2006; 86: 1669-75.

6. Menopausia y transición perimenopáusica. En: Speroff L, Fritz MA. Endocrinología Ginecológica Clínica y Esterilidad, 2a ed. Barcelona: Lippincott Williams y Wilkins; 2006: 621-88.

7. Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: the study of women’s health across the nation. Arch Intern Med 2008; 168: 1568-75.

8. Kilic S, Yilmaz N, Erdogan G, Aydin M, Tasdemir N, Doganay M et al. Effect of non-oral estrogen on risk markers for metabolic syndrome in early surgically menopausal women. Climacteric 2010; 13: 55-62.

9. Korljan B, Bagatin J, Kokic S, Berovic MN, Barsic OS, Dekovic A. The impact of hormone replacement therapy on metabolic syndrome components in perimenopausal women. Med Hypotheses 2010; 74: 162-3.

10. Lobo RA. Metabolic syndrome after menopause and the role of hormones. Maturitas 2008; 60: 10-8.